This 401(k) Mistake Could Cost You Your Match
Accumulation Trumps Allocation in Your Retirement Portfolio
Does That Defrosting Tray Seen on TV Really Save Time?
The 3 Most Successful IPOs of 2014 (So Far)
Johnson & Johnson Launches Offer for Crucell
Giant drugmaker Johnson & Johnson has agreed to buy Dutch vaccine maker Crucell. The deal will give J&J a bigger piece of the vaccine market and better access to emerging markets.
Still in hot water over its "phantom recall" of a Motrin product, Johnson & Johnson looks to expand its share of the vaccine market with purchase of Dutch pharma company Crucell.
Novavax (NVAX) shares soared some 10 percent today after the small clinical-stage biotechnology company announced positive preclinical results for...